🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Dresden
Clinical trial register · Germany

Clinical Trials in Dresden, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca48 Technische Universität Dresden42 Janssen Research & Development, LLC33 Novartis Pharmaceuticals29 Merck Sharp & Dohme LLC22
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Dresden

707 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
2,554
Aachen, Amberg, Bad Oeynhausen, Berlin, Bochum, Dresden, Essen, Falkensee
2024-03-29
Active, closed
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767Bladder Cancer
DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
230
Munich, Regensburg, Dresden, Halle, Berlin
2024-03-28
Active, closed
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934Ulcerative Colitis
Gilead Sciences
Phase 2
228
Dresden, Halle, Kiel, Ulm
2024-03-27
Recruiting
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
NCT06093672Polycythemia Vera
DrugHydroxyurea
Italfarmaco
Phase 3
220
Mannheim, Dresden, Halle, Hamburg
2024-03-26
Recruiting
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT06072781Low Grade Serous Ovarian Cancer
DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole
Verastem, Inc.
Phase 3
270
Frankfurt am Main, Berlin, Dresden, Essen, Hamburg, Mannheim, Ulm
2024-03-18
Recruiting
Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection
NCT06377462VEXAS Syndrome
Technische Universität Dresden
Observational
500
Aachen, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen, Hamburg, Jena
2024-03-13
Recruiting
The NEU-STIM Trial
NCT05942924Infant, Premature, Diseases, Birth, Preterm
Leiden University Medical Center
Not applicable
3,280
Dresden, Düsseldorf, Tübingen
2024-03-11
Recruiting
Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs
NCT06268769Immunosuppression
DrugsTacrolimus Pill·Envarsus·Tacrolimus
Edward Geissler
Phase 4
300
Aachen, Berlin, Dresden, Hamburg, Hanover, Jena, Mainz, Münster
2024-03-09
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
731
Augsburg, Bad Bentheim, Berlin, Bochum, Darmstadt, Dresden, Dülmen, Düsseldorf
2024-03-09
Recruiting
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381Aortic Stenosis
DrugPelacarsen
Novartis Pharmaceuticals
Phase 2
502
Frankfurt am Main, Kaiserslautern, Dresden, Leipzig, Ahaus, Berlin, Bonn, Essen
2024-03-07
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Aachen, Bad Friedrichshall, Bad Homburg, Berlin, Bielefeld, Cologne, Dresden, Essen
2024-03-05
Recruiting
Assessing Habitual, Goal-Directed, and Pavlovian Influences in Alcohol Use Disorder
NCT06701500Alcohol Use Disorder (AUD), Alcoholism, Substance Use Disorders
Technische Universität Dresden
Observational
180
Dresden
2024-03-02
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118Dermatitis Atopic
DrugsPimecrolimus·Amlitelimab·Tacrolimus
Sanofi
Phase 3
464
Berlin, Blankenfelde-Mahlow, Dresden, Frankfurt, Lübeck, Witten
2024-02-29
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Dresden, Essen, Hamburg, Mannheim, Ulm
2024-02-27
Recruiting
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
NCT05836896Neoplasms, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma, Refractory
Technische Universität Dresden
Phase 1
16
Dresden
2024-02-15
Active, closed
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
NCT06380738Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Observational
111
Aschaffenburg, Augsburg, Bergisch Gladbach, Berlin, Bonn, Cologne, Dresden, Duisburg
2024-02-14
Active, closed
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
NCT05990738Small Cell Lung Carcinoma (SCLC)
DrugsObrixtamig·Topotecan
Boehringer Ingelheim
Phase 1
69
Dresden, Erlangen, Heidelberg, Mainz, Würzburg
2024-02-14
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin
Boehringer Ingelheim
Phase 3
428
Augsburg, Berlin, Cologne, Dresden, Giessen, Heidelberg, Oldenburg, Tübingen
2024-02-09
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Berlin, Dresden
2024-02-05
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
122
Dresden, Essen, München
2024-02-01
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
617
Berlin, Bochum, Darmstadt, Dessau, Dresden, Düsseldorf, Erlangen, Frankfurt
2024-01-30
Recruiting
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
NCT05902169Glioblastoma, Recurrent Glioblastoma, GBM
DrugsTemodal·Lomustine·Temozolomide·Carboplatin
CarThera
Phase 3
560
Berlin, Chemnitz, Cologne, Dresden, Essen, Münster
2024-01-29
Recruiting
Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation
NCT06482138Covid19, Olfactory Dysfunction
Universitaire Ziekenhuizen KU Leuven
Not applicable
240
Dresden, Frankfurt am Main
2024-01-24
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
DrugsBelumosudil·Prednisolone·Prednisone
Sanofi
Phase 3
260
Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Kiel, Münster, Regensburg
2024-01-23
Active, closed
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337Metastatic Breast Cancer
DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel
DualityBio Inc.
Phase 3
541
Erlangen, Wiesbaden, Bottrop, Cologne, Witten, Dresden, Berlin
2024-01-18
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Berlin, Cologne, Dresden, Frankfurt am Main, Heidelberg, Immenhausen, Moers
2024-01-18
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
NCT06008197Heart Failure, Acute Heart Failure
DrugFinerenone
Colorado Prevention Center
Phase 3
5,200
Lübeck, Berlin, Jena, Dresden, Giessen, Regensburg
2024-01-17
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
774
Berlin, Bramsche, Dresden, Düsseldorf, Hamburg, Kiel, Langenau, Leipzig
2024-01-17
Recruiting
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
NCT05949125Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
AvenCell Europe GmbH
Phase 1
37
Ulm, Munich, Würzburg, Marburg, Dresden, Berlin, Cologne, Essen
2024-01-03
Active, closed
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879Essential Thrombocythemia
DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib
Merck Sharp & Dohme LLC
Phase 3
340
Aachen, Dresden, Halle
2023-12-31
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Bielefeld, Bochum, Dresden, Düsseldorf, Erbach im Odenwald, Essen, Heidelberg, Jena
2023-12-27
Active, closed
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
NCT06140836Carcinoma, Non-Small-Cell Lung
DrugsRepotrectinib·Crizotinib
Bristol-Myers Squibb
Phase 3
190
Esslingen am Neckar, Würzburg, Oldenburg, Berlin, Cologne, Dresden, Gauting, Immenhausen
2023-12-21
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566CLL/SLL
DrugLisaftoclax
Ascentage Pharma Group Inc.
Phase 3
400
Dresden, München
2023-12-20
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06285318Relapsed/Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.
Observational
900
Chemnitz, Dresden, Hamburg, Hanover, Heidelberg, Nuremberg, Würzburg
2023-12-18
Recruiting
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
220
Aachen, Augsburg, Bergisch Gladbach, Bottrop, Bremen, Cologne, Dresden, Hanover
2023-12-15
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)
DrugsOdronextamab·Prednisone/Prednisolone·Cytoxan·Adriamycin
Regeneron Pharmaceuticals
Phase 3
904
Stuttgart, Mutlangen, Frankfurt am Main, Essen, Mainz, Homburg, Dresden, Berlin
2023-12-13
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Bielefeld, Bochum, Böblingen, Dresden, Düsseldorf, Erbach im Odenwald, Essen, Giessen
2023-12-13
Recruiting
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
NCT06091254Follicular Lymphoma (FL)
DrugsOdronextamab·Prednisone/Prednisolone·Cytoxan·Adriamycin
Regeneron Pharmaceuticals
Phase 3
822
Stuttgart, Würzburg, Mutlangen, Frankfurt am Main, Mainz, Dresden, Berlin, Kiel
2023-12-12
Active, closed
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)
NCT06111586Type 1 Diabetes Mellitus
DrugFrexalimab
Sanofi
Phase 2
197
Dresden, Hanover, Oldenburg in Holstein, Ulm
2023-12-11
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
362
Göttingen, Stade, Dresden, Berlin, Mainz, Münster, Tübingen
2023-12-07
Active, closed
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT05689671Non-Small Cell Lung Cancer Metastatic
DrugsAbraxane·Tecentriq·Atezolizumab·Nab-paclitaxel
Nikolaj Frost MD
Phase 4
136
Amberg, Augsburg, Bad Homburg, Berlin, Bielefeld, Cologne, Dresden, Essen
2023-12-06
Recruiting
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
NCT06317805Pulmonary Arterial Hypertension
AOP Orphan Pharmaceuticals AG
Phase 4
110
Berlin, Dresden, Greifswald
2023-12-06
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
DrugsAbraxane·Adriamycin·Taxol·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
710
Heilbronn, Mannheim, Ravensburg, Tübingen, Munich, Essen, Dresden, Berlin
2023-12-06
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Tegafur·Capecitabine
AstraZeneca
Phase 3
760
Berlin, Bonn, Dortmund, Dresden, Erlangen, Esslingen A. N., Frankfurt, Hamburg
2023-12-04
Recruiting
Multi-professional Care Pathway and Network for the Promotion of Needs-oriented, Resident-oriented Exercise Therapy for Oncological Patients
NCT06185777Cancer, Exercise, Implementation
University Hospital Heidelberg
Not applicable
2,500
Freiburg im Breisgau, Heidelberg, Tübingen, Frankfurt am Main, Mainz, Dresden, Berlin
2023-12-01
Recruiting
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
NCT07630545Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease
Mission Therapeutics
Phase 1
106
Dresden
2023-11-30
Active, closed
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471NonSegmental Vitiligo
DrugPovorcitinib
Incyte Corporation
Phase 3
450
Bad Bentheim, Berlin, Dresden, Hamburg, Mahlow, Münster
2023-11-27
Active, closed
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837Pulmonary Disease, Chronic Obstructive
DrugGSK3862995B
GlaxoSmithKline
Phase 1
127
Ahrensburg, Berlin, Dresden, Frankfurt, Hamburg, Hanover, Immenhausen, Leipzig
2023-11-27
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate
AstraZeneca
Phase 3
1,898
Bergisch Gladbach, Berlin, Braunschweig, Cologne, Dresden, Duisburg, Frankfurt, Frankfurt am Main
2023-11-21
Active, closed
The PEERLESS II Study
NCT06055920Pulmonary Embolism
Inari Medical
Not applicable
1,200
Augsburg, Bad Krozingen, Berlin, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2023-11-17
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Karlsruhe, Krefeld, Velbert, Dresden, Kiel
2023-11-16
Active, closed
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478Chronic Spontaneous Urticaria
DrugsOmalizumab·Remibrutinib
Novartis Pharmaceuticals
Phase 3
470
Freiburg im Breisgau, Munich, Hamburg, Göttingen, Stade, Dresden, Leipzig, Halle
2023-11-15
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsDatopotamab deruxtecan·Epirubicin·Xeloda·Olaparib
AstraZeneca
Phase 3
1,902
Augsburg, Berlin, Dessau, Dresden, Erlangen, Essen, Esslingen am Neckar, Frankfurt am Main
2023-11-14
Active, closed
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
NCT06107413Unresectable Metastatic Colorectal Cancer
DrugsFolinic acid·Telisotuzumab Adizutecan·Fluorouracil·Irinotecan
AbbVie
Phase 2
280
Mannheim, Tübingen, Ulm, Dresden, Berlin, Hamburg
2023-11-12
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
556
Freiburg, Göttingen, Essen, Chemnitz, Dresden, Hamburg
2023-11-12
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
1,571
Darmstadt, Bielefeld, Bochum, Bonn, Mainz, Dresden, Leipzig, Magdeburg
2023-11-08
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
DrugDapagliflozin
AstraZeneca
Phase 3
1,835
Aachen, Bad Oeynhausen, Berlin, Dresden, Hanover, Mainz, München
2023-11-07
Recruiting
CeraFlex PFO Closure System PMCF Study
NCT06120270Patent Foramen Ovale
Lifetech Scientific (Shenzhen) Co., Ltd.
Observational
180
Bremen, Dresden, Fürth, Hamburg, Leipzig, Munich, Trier, Tübingen
2023-11-03
Recruiting
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
NCT05566769Neuromyelitis Optica
Ad scientiam
Not applicable
103
Dresden, Essen, Munich
2023-11-03
Active, closed
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725Spasticity as Sequela of Stroke
Ipsen
Observational
1,057
Altenburg, Berlin, Dresden, Düsseldorf, Essen, Kiel, Lübeck, Mainz
2023-11-01
Active, closed
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332Metastatic Uveal Melanoma
DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy
IDEAYA Biosciences
Phase 2/3
420
Heidelberg, Cologne, Essen, Dresden, Berlin
2023-10-31
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626Metastatic Breast Cancer
DrugsAbemaciclib·Fulvestrant
LeonaBio
Phase 3
600
Dresden, München
2023-10-31
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
612
Freiburg im Breisgau, Würzburg, Ludwigshafen, Cologne, Dresden, Berlin, Erlangen, Hanover
2023-10-27
Recruiting
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
NCT06054035Type2diabetes, PreDiabetes, Renal Failure
DrugDapagliflozin
University Hospital Tuebingen
Phase 4
170
Berlin, Dresden, Düsseldorf, Heidelberg, Leipzig, Lübeck, München, Tübingen
2023-10-26
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
895
Berlin-Zehlendorf, Bonn, Braunschweig, Dresden, Freiburg im Breisgau, Gauting, Georgsmarienhütte, Gütersloh
2023-10-24
Active, closed
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
960
Bad Krozingen, Berlin, Dresden
2023-10-20
Active, closed
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326Adenocarcinoma, Pancreatic Ductal
DrugsAutogene cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab
Genentech, Inc.
Phase 2
260
Berlin, Bochum, Cologne, Dresden, Essen, Frankfurt, Hamburg, Heidelberg
2023-10-18
Active, closed
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806Multiple Myeloma
DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan
Celgene
Phase 3
79
Heidelberg, Ulm, Nuremberg, Cologne, Leipzig, Dresden, Essen, Hamburg
2023-10-16
Recruiting
Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases
NCT06396871NAFLD, Diabetes Mellitus, Obesity
Technische Universität Dresden
Observational
180
Dresden
2023-10-16
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Berlin, Dresden, Erlangen, Gauting, Großhansdorf, Mainz
2023-10-13
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
684
Bad Bentheim, Berlin, Bonn, Dresden, Dülmen, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau
2023-10-12
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
NCT06095102Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
311
Berlin, Bochum, Darmstadt, Dresden, Frankfurt am Main, Hamburg, Schwerin, Witten
2023-10-12
By invitation
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugLitifilimab
Biogen
Phase 3
306
Erlangen, Bad Bentheim, Oldenburg, Münster, Dresden, Halle, Berlin
2023-10-03
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
106
Munich, Würzburg, Dresden, Jena, Berlin, Essen, Hamburg, Hanover
2023-10-02
Active, closed
An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT05900141Hyperlipoproteinemia (a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
41
Frankfurt am Main, Berlin, Cloppenburg, Dresden, Erlangen, Mainz, München, Ulm
2023-09-29
Recruiting
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
NCT06043817Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament
Phase 1/2
345
Berlin, Dresden
2023-09-26
Active, closed
MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect
NCT05816122Multiple Sclerosis
Ad scientiam
Not applicable
336
Bayreuth, Dresden, Erbach im Odenwald
2023-09-22
Active, closed
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06088290Leiomyosarcoma
DrugsLurbinectedin·Doxorubicin
PharmaMar
Phase 3
469
München, Bad Saarow, Dresden, Hanover, Heidelberg, Manheim, Münster, Tübingen
2023-09-21
Active, closed
Avacostar - (PASS)
NCT05897684ANCA-associated Vasculitis
Vifor Fresenius Medical Care Renal Pharma
Observational
507
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Göttingen, Hamburg, Hanover
2023-09-11
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
DrugsCyclophosphamid·Rituximab
Alentis Therapeutics AG
Phase 2
80
Berlin, Cologne, Dresden, Essen, Hanover, Leipzig, Lübeck, München
2023-09-07
Active, closed
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398Metastatic Castrate-sensitive Prostate Cancer
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
420
Aachen, Augsburg, Cologne, Dresden, Lübeck, München, Nürtingen, Würzburg
2023-08-31
Active, closed
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
NCT05885555Primary Immune Thrombocytopenia (ITP)
DrugIanalumab
Novartis Pharmaceuticals
Phase 2
41
Dresden, Jena, Giessen
2023-08-16
Active, closed
The BD Liverty™ TIPS Stent Graft Study
NCT05711316Portal Hypertension, TIPS
C. R. Bard
Not applicable
177
Berlin, Bonn, Dresden, Frankfurt, Hanover, Münster
2023-08-08
Recruiting
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
NCT05538806Pleural Mesothelioma
NovoCure Ltd.
Observational
198
Gauting, Regensburg, Harburg, Bremen, Göttingen, Dresden, Berlin, Cologne
2023-08-01
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Kassel, Dresden, Giessen, Regensburg
2023-07-31
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
DrugUpadacitinib
AbbVie
Phase 3
1,014
Cologne, Mainz, Dresden, Buch, Frankfurt am Main
2023-07-25
Recruiting
Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety
NCT06126601Pancreatectomy, Hyperamylasemia, Pancreatitis, Acute
Technische Universität Dresden
Observational
150
Dresden
2023-07-18
Active, closed
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
NCT05968430Hypertension
Mineralys Therapeutics Inc.
Phase 3
1,076
Berlin, Deggingen, Dresden, Leipzig
2023-07-14
Recruiting
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
NCT05332561Early-stage Breast Cancer
DrugsPhesgo·Ipatasertib·Inavolisib·Sacituzumab Govitecan
German Cancer Research Center
Phase 2
240
Heidelberg, Tübingen, Augsburg, Erlangen, Ulm, Würzburg, Dresden, Berlin
2023-06-29
Active, closed
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
NCT05879978Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms
DrugsEzabenlimab·Obrixtamig
Boehringer Ingelheim
Phase 1
45
Dresden, Frankfurt
2023-06-27
Recruiting
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
NCT05820841Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
DrugsR-miniCHOP·Acalabrutinib
Universität des Saarlandes
Phase 3
330
Homburg, Aschaffenburg, Berlin, Dresden, Giessen, Greifswald, Halle, Karlsruhe
2023-06-07
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
Dresden, Munich, Würzburg
2023-06-07
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Berlin, Cologne, Dresden, Essen, Gauting, Großhansdorf, Stuttgart, Würzburg
2023-05-31
Active, closed
Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy
NCT05833438Acute Myeloid Leukemia (AML)
University of Leipzig
Phase 2
45
Berlin, Chemnitz, Cottbus, Dresden, Heidelberg, Leipzig, Mönchengladbach, München
2023-05-17
Active, closed
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
NCT05791201Type 1 Diabetes
Vertex Pharmaceuticals Incorporated
Phase 1/2
7
Dresden
2023-05-16
Active, closed
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469Myeloid Diseases
Novartis Pharmaceuticals
Phase 1
71
Dresden, Leipzig, Lübeck
2023-05-08
Active, closed
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
NCT05876754Cholangiocarcinoma
DrugIvosidenib
Servier Affaires Médicales
Phase 3
299
Berlin, Dresden, Düsseldorf, Frankfurt, Freiburg im Breisgau, Hanover, München
2023-05-03
Active, closed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501Renal Cell Carcinoma
DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda
Hoffmann-La Roche
Phase 2
199
Dresden, Hamburg, Hanover, München, Nürtingen, Ulm
2023-04-21
Active, closed
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 2
999
Augsburg, Bad Bentheim, Berlin, Dresden, Münster, Osnabrück, Rostock, Witten
2023-04-03
Active, closed
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562Neoplasms, Rectal
DrugDostarlimab
GlaxoSmithKline
Phase 2
154
Berlin, Dresden, Düsseldorf, Frankfurt, München
2023-04-03
Rows per page Showing 301–400 of 707
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/dresden?page=4

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 707 of those studies with a site in Dresden.

How many clinical trials are recruiting in Dresden?

356 of the 707 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 17 have not yet opened recruitment, 321 are active but closed to new participants, and 13 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.